Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.

@article{Poovassery2015AntibodyTO,
  title={Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.},
  author={Jayakumar S. Poovassery and Jeffrey C Kang and Dongyoung Kim and Raimund J. Ober and E Sally Ward},
  journal={International journal of cancer},
  year={2015},
  volume={137 2},
  pages={267-77}
}
Dysregulated expression and/or mutations of the various components of the phosphoinositide 3-kinase (PI3K)/Akt pathway occur with high frequency in prostate cancer and are associated with the development and progression of castration resistant tumors. However, small molecule kinase inhibitors that target this signaling pathway have limited efficacy in inhibiting tumor growth, primarily due to compensatory survival signals through receptor tyrosine kinases (RTKs). Although members of the… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Multiple studies indicate a critical role for HER3 in the development of resistance against both HER - targeted therapies and PI3K / Akt pathway inhibitors .
Multiple studies indicate a critical role for HER3 in the development of resistance against both HER - targeted therapies and PI3K / Akt pathway inhibitors .
All Topics